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Objectives This study assessed the ability of the SYNTAX score (SXscore) to stratify risk in patients
treated with percutaneous coronary intervention (PCI) using zotarolimus-eluting or everolimus-elut-
ing stents.
Background The SXscore can identify patients treated with PCI who are at highest risk of adverse events.
Methods The SXscore was calculated prospectively in 2,033 of the 2,292 patients enrolled in the
RESOLUTE All Comers study (RESOLUTE III All Comers Trial: A Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). Clinical out-
comes in terms of a patient-oriented composite endpoint (POCE) of all-cause death, myocardial in-
farction (MI), and repeat revascularization; the individual components of POCE; target lesion failure
(TLF) (a composite of cardiac death, target-vessel MI, and clinically driven target lesion revasculariza-
tion); and stent thrombosis were subsequently stratiﬁed according to SXscore tertiles: SXscoreLOW
9 (n  698), 9 SXscoreMID 17 (n  676); SXscoreHIGH 17 (n  659).
esults At 12-month follow-up, rates of POCE, MI, repeat revascularization, TLF, and the composite of
eath/MI were all signiﬁcantly higher in patients in the highest SXscore tercile. Rates of stent thrombosis
ere all highest in the SXscoreHIGH tertile (p  0.05). After multivariate adjustment, the SXscore was
identiﬁed as an independent predictor of POCE, MI, repeat revascularization, and TLF (p  0.05 for all).
At 12-month follow-up, the SXscore, ACEF score, and Clinical SXscore had C-statistics of 0.57, 0.78, and
0.67, respectively, for mortality and of 0.62, 0.56, 0.63, respectively, for POCE. No signiﬁcant between-
stent differences were observed for TLF or POCE in any of the SXscore tertiles.
Conclusions The SYNTAX score is able to stratify risk amongst an all-comers population treated
with PCI with second-generation drug-eluting stents (DES); however, improvements can be made
with the inclusion of clinical variables. (RESOLUTE III All Comers Trial: A Randomized Comparison of
a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Interven-
tion; NCT00617084) (J Am Coll Cardiol Intv 2011;4:432–41) © 2011 by the American College of
Cardiology Foundation
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433The SYNTAX score (SXscore) is a comprehensive scoring
system made up of angiographic variables (1,2). It was
originally developed to quantify the complexity of coronary
artery disease (CAD); however, subsequent studies have
demonstrated its ability to identify patients treated by
percutaneous coronary intervention (PCI) who are at high-
est risk of adverse events (3–8).
Currently, prospective studies assessing its use in patients
treated with PCI are limited to the SYNTAX (Synergy
between PCI with Taxus and Cardiac Surgery) study (4),
which only enrolled patients with complex CAD (3-vessel
and/or left main disease), and the LEADERS (Limus
Eluted from A Durable versus ERodable Stent coating)
study (3), which was more reflective of everyday clinical
practice through its all-comers design. Of note, other than the
703 patients treated with the biolimus-eluting stent with a
biodegradable polymer in the LEADERS SXscore substudy
(3), all other studies evaluating the SXscore have assessed
utcomes in patients treated with first-generation drug-
luting stents (DES) (4–9). Second-generation DES were
eveloped on the background of safety concerns with these
rst-generation devices, and early data suggest significantly
mproved outcomes (10–12); however, the effect of this on the
enefits of using the SXscore to stratify risk remains to be
stablished.
The RESOLUTE All Comers study (RESOLUTE III All
omers Trial: A Randomized Comparison of a Zotarolimus-
luting Stent With an Everolimus-Eluting Stent for Percutane-
us Coronary Intervention) (13) randomized 2,292 patients to
reatment with the Resolute zotarolimus-eluting stent (R-
ES) (Medtronic Inc., Santa Rosa, California) or the
ience V everolimus-eluting stent (EES) (Abbott Vascular,
anta Clara, California). Results demonstrated that R-ZES
as noninferior to EES with respect to the 12-month
rimary clinical endpoint of target lesion failure (TLF)
R-ZES 8.2% vs. EES 8.3%, pnoninferiority  0.001), a
composite of cardiac death, target-vessel myocardial infarc-
tion (MI), and clinically driven target lesion revasculariza-
tion (TLR) and the 13-month secondary angiographic
endpoint of in-stent diameter stenosis (R-ZES 21.65 
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Leeuwarden, the Netherlands; #Department of Cardiology, Herzzentrum Leipzig,
Leipzig, Germany; **Department of Cardiology, University Hospital Munich (Innen-
stadt), Munich, Germany; ††Department of Cardiology, Onze Lieve Vrouw Ziekenhuis,
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this sub-study of the RESOLUTE All Comers trial the
prognostic value of the SXscore was assessed in isolation
and in comparison with the Age, Creatinine and Ejection
Fraction (ACEF score) (14,15) and the clinical SYNTAX
score (CSS), (16) in an all-comers population treated with
second-generation DES.
Methods
Study population. The methods of the RESOLUTE All
Comers study have been published previously (13). In brief,
the study applied an all-comers approach to recruit 2,292
patients with chronic stable
CAD or acute coronary syn-
dromes including ST-segment
elevation myocardial infarction
that were eligible for enrollment
if they had1 lesion with diam-
eter stenosis (DS) 50% and a
reference vessel diameter be-
tween 2.25 and 4.0 mm. No
restriction was placed on the
number of lesions or vessels
treated or the number of stents
implanted. Principal exclusion
criteria were: allergy to study
medication, metal alloys, or con-
trast media; planned surgery
within 6 months of PCI unless
the dual antiplatelet therapy could
be maintained throughout the
perioperative period; pregnancy;
participation in another trial be-
fore reaching the primary end-
point; and lastly, inability to give
informed consent. The study
complied with the Declaration
of Helsinki and was approved by
all institutional ethics commit-
Rotterdam, the Netherlands; and §§§Department of Interventional Cardiology, Bern
University Hospital, Bern, Switzerland. This study was funded by Medtronic
CardioVascular, Santa Rosa, California. Dr. Garg has received honoraria from
Medtronic Cardiovascular. Dr. Kalbaek is consultant for Abbott Vascular and has
board membership at Boston Scientific and Medtronic. Dr. Linke is a consultant for
Medtronic (transcatheter valve only). Dr. Manoharan is a consultant for Medtronic
and has received travel expenses from Medtronic. Dr. Silber has been a speaker for
Abbott Vascular and received travel reimbursement. Dr. Bartorelli is an advisory
board member for Abbott Vascular. Dr. Windecker is a consultant for and receives
fees from Abbott Vascular, Boston Scientific, Cordis, Medtronic, and Biosensors.
Drs. DiMario, Kornowski, and Wijns report that their institutions have received
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Abbreviations
and Acronyms
ACEF score  Age, Creatinine
and Ejection Fraction
CAD  coronary artery
disease
CEC  clinical events
committee
CSS  clinical SYNTAX
score
DES  drug-eluting stent(s)
ECG  electrocardiograph
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
POCE  patient-oriented
composite endpoint
R-ZES  Resolute
zotarolimus-eluting stent(s)
ST  stent thrombosis
SXscore  SYNTAX score
TLF  target lesion failure
TLR  target lesion
revascularizationManuscript received August 20, 2010; revised man
accepted January 20, 2011.uscript received January 11, 2011,
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434tees. All patients provided written informed consent for
participation in the trial.
Randomization and procedures. Patients were randomly allo-
cated on a 1:1 basis to treatment with R-ZES or EES and to
12-month clinical follow-up only or in addition to active
angiographic follow-up at 13-months, on a 1:4 basis with a
factorial design. A blinded independent clinical events com-
mittee (CEC) adjudicated all endpoints, and independent study
monitors verified all case reports from data on-site. The operators
were by necessity aware of the assigned study stent during PCI
and angiographic follow-up, but patients and staff involved in
follow-up assessment were blinded to the allocated stent type.
The R-ZES were available in diameters of 2.25 to 4.0
mm and in lengths of 8 to 30 mm, whereas EES were
available in diameters of 2.25 to 4.0 mm and in lengths of
8 to 28 mm. Balloon angioplasty and stent implantation
were performed according to standard technique, and direct
stenting was allowed. The aim was to obtain full lesion
coverage with 1 or several stents. No mixture of DES was
permitted within a given patient, unless the operator was
unable to insert the study stent, in which case crossover to
another nonstudy device of the operator’s choice was possible.
Procedural anticoagulation was achieved with unfraction-
ated heparin 5,000 IU or 70 to 100 IU/kg, whereas the use
of glycoprotein IIb/IIIa inhibitors was left to the discretion
of the operator. Before the procedure, all patients enrolled
into the study received 75 mg of acetylsalicylic acid,
whereas the 300- to 600-mg loading dose of clopidogrel was
only given if no clopidogrel had been administrated in the
previous 7 days. All patients were discharged on 75 mg of
acetylsalicylic acid indefinitely and clopidogrel 75 mg for6
months after the index procedure. In the case of intercurrent
revascularization procedures needing stent implantation,
treating cardiologists were encouraged to use study stents.
Follow-up. Adverse events were assessed in hospital, and
clinical follow-up was performed at 1, 6, and 12 months.
Additional clinical follow-up is planned at yearly intervals to
5 years. One in 5 patients was asked to return for angio-
graphic follow-up at 13 months.
SXscore. The SXscore for each patient was calculated pro-
pectively by scoring all coronary lesions with a DS50%, in
essels1.5 mm, with the SXscore algorithm that is described
n full elsewhere (1,2) and available at the SYNTAX Score
ebsite (17). All angiographic variables pertinent to
Xscore calculation were computed by 2 core laboratory
nalysts (Cardialysis B.V., Rotterdam, the Netherlands), who
ere blinded to all clinical data, presentation, and outcomes. In
he event of disagreement, the opinion of a third analyst was
ought, and the final decision was established by consensus.
atients with occluded infarct-related arteries were scored as
cclusions of unknown duration in a similar manner as any
hronically occluded artery. In addition, those patients with
esions due to restenosis or in-stent restenosis were scored in
he same manner as if the lesion were a de novo lesion. elthough this methodology was not described in the original
escription of the SXscore, it has previously been applied to
ther all-comers (3,6) and ST-segment elevation myocardial
nfarction populations (9).
ACEF score and CSS. The ACEF score was calculated with
the combination of the patient’s age, left ventricular ejection
fraction, and serum creatinine as described elsewhere (14).
Similarly, the CSS was calculated with the combination of
the SXscore and the patient’s age, left ventricular ejection
fraction, and creatinine clearance as described in the primary
manuscript (16).
Study endpoints. The primary endpoint of this analysis was
a patient-oriented composite endpoint (POCE) of all-cause
death, any MI, and any repeat revascularization. Secondary
endpoints included the individual components of the
POCE, together with 1-year rates of cardiac death, target
vessel MI, clinically indicated TLR, a safety composite of
death/MI, TLF (a composite of cardiac death, target-vessel
MI, and TLR), and definite, definite/probable, and any
stent thrombosis (ST).
Deﬁnitions. Definitions of all endpoints are provided in the
rimary manuscript (13). All deaths were considered cardiac
nless an undisputed noncardiac cause was present. Myo-
ardial infarction was defined according to an extended
istorical protocol definition and according to Academic
esearch Consortium definitions (18,19). A Q-wave MI
equired, in the absence of cardiac enzyme data, a history of
hest pain or other acute symptoms consistent with myo-
ardial ischemia together with new pathological Q waves in
2 contiguous electrocardiograph (ECG) leads as as-
essed by the core laboratory or CEC. In the presence of
levated cardiac enzymes, new pathological Q waves in
2 contiguous ECG leads as assessed by the core
aboratory or CEC were sufficient to diagnose a Q-wave
I. In the absence of an ECG, a Q-wave MI could be
djudicated on the basis of the clinical scenario and
ppropriate cardiac enzyme data.
A TLR was considered clinically indicated if angiography
uring follow-up showed a DS 50% (core laboratory
uantitative coronary angiography assessment) and if 1 of
he following occurred: 1) a positive history of recurrent
ngina pectoris, presumably related to the target vessel; 2)
bjective signs of ischemia at rest (ECG changes) or during
xercise test (or equivalent), presumably related to the target
essel; 3) abnormal results of any invasive functional diag-
ostic test (e.g., fractional flow reserve); or 4) a TLR with a
S 70% even in the absence of the aforementioned
schemic signs or symptoms. An ST was defined according
o the Academic Research Consortium definitions (18).
Statistical methods. All patients with a calculated SXscore
ere included in the analysis. All variables were stratified
ccording to SXscore tertiles. Discrete data were summa-
ized as frequencies (%), whereas continuous data were
xpressed as mean  SD. Testing for (linear) trends was
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435done with generalized linear models with SYNTAX tertiles
as a covariable for continuous variables and the Cochran-
Armitage test for trend in categorical data. The Fisher exact
test was used to analyze differences in outcome between
stents. Survival curves were constructed for time-to-event
variables with Kaplan-Meier estimates and compared by the
log-rank test. Patients lost to follow-up were considered at
risk until the date of last contact, at which point they were
censored. A Cox multivariate model was performed with the
covariates sex, age 65 years, presence of diabetes, presen-
tation with acute MI, stent type, and SXscore. C-statistics
from receiver operator characteristic curves were used to
compare the discrimination of the SXscore, ACEF score,
and CSS score. A p value of 0.05 was considered
significant, and all tests were 2-tailed. Data were analyzed
with SAS software (SAS, version 9.2, Cary, North Caro-
lina) by a dedicated statistician.
Results
The SXscore was available for 2,033 (88.7%) of 2,292
patients enrolled in the study, with the presence of coronary
artery bypass grafts (224 patients) as the major reason for
inability to calculate the score. The SXscore ranged from 0
to 54.5, with a mean  SD of 14.6  9.2 and a median of
13.0 (interquartile range 7 to 20). In this analysis patients
were categorized according to tertiles of the SXscore defined
Table 1. Baseline Clinical Characteristics
Variable
SXscore <9
(n  698)
Baseline characteristics
Male 71.2% (497)
Age, yrs 63.0 10.9
Risk factors
Previous MI 26.5% (182)
Diabetes mellitus 19.3% (135)
Arterial hypertension 70.6% (493)
Hypercholesterolemia 65.6% (458)
Premature CAD in ﬁrst-degree relative 36.0% (214)
Current smoker 25.5% (178)
Previous PCI 31.2% (218)
Creatinine clearance, ml/1.73 m2 96.2 34.4
Left ventricular ejection fraction 30% 2.0% (8)
Multivessel disease 32.4% (226)
SXscore 5.7 2.4
Indication for treatment
Revascularization for angina or MI 86.8% (606)
Stable angina 37.5% (262)
Unstable angina 21.6% (151)
Acute MI 27.7% (193)
Values are given as % (n) or mean SD.CAD coronary artery disease; MImyocardial infarction; PCI percutaneous coronary intervention; Sas: SXscoreLOW 9 (n  698); 9 SXscoreMID 17 (n 
76); SXscoreHIGH 17 (n  659).
Baseline clinical characteristics. Baseline clinical parameters
stratified according to SXscore tertiles are presented in
Table 1. Advanced patient age, male sex, the presence of
diabetes mellitus and multivessel disease, and presentation
with an acute MI were all significantly more common in the
SXscoreHIGH tertile. Conversely, hypercholesterolemia and
resentation with stable angina were significantly more
requent in the SXscoreLOW tertile.
Baseline angiographic characteristics. Baseline lesion and
rocedural characteristics are shown in Table 2. The fre-
uency of triple-vessel disease and all markers of increased
esion complexity such as the presence of bifurcation lesions
nd total occlusions were all significantly higher in the
XscoreHIGH tertile, in line with its method of derivation.
orrespondingly the number of treated lesions, stents im-
lanted, and mean stent length were also higher in the
XscoreHIGH tertile.
Clinical outcomes. Clinical outcomes at 1 year are shown in
able 3, whereas cumulative survival curves are displayed in
igure 1. Overall, the POCE, the safety endpoint of
eath/MI, and the rates of MI and repeat revascularization
ere all significantly higher in the SXscoreHIGH tertile. No
trends were noted among rates of death and definite,
definite/probable, or any ST and the SXscore tertile of the
patient.
9 <SXscore <17
(n  676)
SXscore >17
(n  659) p Value
76.9% (520) 78.8% (519) 0.001
63.0 10.8 65.5 11.0 0.001
24.8% (164) 28.7% (185) 0.37
23.2% (157) 24.7% (163) 0.02
71.3% (482) 68.3% (450) 0.35
64.1% (433) 59.8% (394) 0.03
37.7% (218) 30.7% (169) 0.07
29.3% (198) 29.1% (192) 0.13
26.6% (180) 29.9% (197) 0.57
96.6 34.7 90.9 34.3 0.006
2.4% (8) 1.6% (6) 0.69
57.0% (385) 78.8% (519) 0.0001
13.3 2.3 25.5 6.7 N/A
88.9% (601) 89.4% (589) 0.14
31.8% (215) 30.2% (199) 0.004
19.7% (133) 14.9% (98) 0.002
37.4% (253) 44.3% (292) 0.0001Xscore SYNTAX score.
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436Multivariate analysis. The results of the Cox multivariable
analysis are shown in Table 4. The SXscore remained an
independent predictor, after adjustment of confounding
factors, of clinical outcomes such as MI, repeat revascular-
ization, TLF, and POCE.
SXscore versus ACEF score versus CSS. Table 5 reports the
respective C-statistics for the SXscore, ACEF score, and
CSS for a range of clinical outcomes at 12-month follow-
up. The discriminatory ability of the SXscore was best for
repeat revascularization, poorest for the assessment of mor-
tality, and comparable to the CSS for the composite
endpoints of TLF and POCE.
Zotarolimus versus everolimus. For illustrative purposes, a
omparison of outcomes amongst patients in each SXscore
ertile stratified according to stent type was performed.
verall rates of TLF, the device-oriented primary endpoint
f the Resolute All Comers study, and the POCE were
omparable between R-ZES and EES in all 3 SXscore
Table 2. Baseline Lesion and Procedural Characteristics
Variable
SXscore <9
(n  698)
Extent of disease
No. of disease lesions 1.5 0.7
1-vessel disease 67.6% (472)
2-vessel disease 29.1% (203)
3-vessel disease 2.1% (15)
Lesion location
Left main stem 0.0% (0)
Right coronary artery 46.8% (327)
Circumﬂex artery 34.1% (238)
LAD artery 51.3% (358)
Proximal LAD involvement 8.7% (61)
All de novo lesions 89.3% (620)
Lesion characteristics
1 bifurcation lesion 25.9% (181)
1 trifurcation lesion 0.6% (4)
1 ostial lesion 1.6% (11)
1 occlusion 3.6% (25)
1 tortuous lesion 24.8% (171)
1 lesion 20 mm 8.0% (55)
1 calciﬁed lesion 3.0% (21)
1 lesion with thrombus 5.8% (40)
1In-stent restenosis lesion 9.1% (63)
Off-label indication* 49.9% (348)
Procedural characteristics
No. of treated lesions 1.2 0.4
No. of stents implanted 1.5 0.8
Total stent length, mm 25.7 16.3
Mean duration of DAPT, days 315 97
Values are given as mean  SD or % (n). *Off-label use included patients with at least 1 of the foll
myocardial infarction (72 h),1 lesion/vessel,2 vessels stented; lesions27 mm, bifurcations,
DAPT dual antiplatelet therapy; LAD left anterior descending artery; SXscore SYNTAX scoroups (p  0.05). Notably, in 659 patients with the mostomplex CAD, mortality was significantly higher in patients
reated with EES (R-ZES 1.3% vs. EES 4.1%, p  0.03),
hereas rates of clinically indicated TLR (7.2% vs. 3.5%,
 0.04) and definite ST (2.2% vs. 0.0%, p  0.006) were
ignificantly higher in those treated with R-ZES.
iscussion
This study, which represents the largest assessment of the
SXscore in patients treated with PCI and is the first to
assess its ability to stratify risk in patients treated entirely
with second-generation DES, demonstrates a consistent
ability of the SXscore to identify patients at highest risk of
adverse events after PCI.
A key to optimizing outcomes in patients undergoing
PCI is the ability to reliably identify those patients at
highest risk of undesired events. With respect to this, the
SXscore has been consistently shown to be an important
9 <SXscore <17
(n  676)
SXscore >17
(n  659) p Value
2.5 1.1 4.0 1.6 0.0001
26.9% (182) 7.4% (49) 0.005
54.3% (367) 36.1% (238) 0.0001
18.8% (127) 56.4% (372) 0.0001
0.6% (4) 5.8% (38) 0.0001
60.7% (410) 75.9% (500) 0.0001
53.3% (360) 74.5% (491) 0.0001
77.4% (523) 95.1% (627) 0.0001
21.0% (142) 44.9% (296) 0.0001
92.5% (620) 90.6% (591) 0.39
56.2% (380) 75.6% (498) 0.0001
3.6% (24) 6.4% (42) 0.0001
3.0% (20) 4.9% (32) 0.0005
25.3% (171) 49.3% (325) 0.0001
45.0% (304) 62.7% (413) 0.0001
29.6% (200) 53.0% (349) 0.0001
10.4% (70) 21.5% (142) 0.0001
6.5% (44) 10.9% (72) 0.0004
5.5% (37) 7.7% (50) 0.30
67.2% (454) 80.9% (533) 0.0001
1.5 0.6 1.9 1.0 0.0001
1.9 1.1 2.6 1.6 0.0001
35.3 22.9 48.1 30.3 0.0001
319 90 308 102 0.20
linical and lesion characteristics: renal insufficiency (140 mol/l), ejection fraction 30%, acute
grafts, in-stent restenosis, unprotected left main, lesions with thrombus, or total occlusion.owing c
bypasstool for risk stratification; however, prior assessments of the
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437score in PCI populations have been limited by being
retrospective (5–9,20) and largely including only those
patients with the most complex CAD (4,7,8,20). In addi-
tion, other than the LEADERS study (3), all other studies
have enrolled patients treated with first-generation DES
(4–9). The current prospective study had an all-comers design,
such that any patient with symptomatic CAD suitable for PCI
who consented to enrollment could be included, thereby
ensuring that the patient cohort provided a good reflection of
those patients routinely seen in “real-world” contemporary
practice. Furthermore, all patients received second-generation
DES, which have been shown to have superior safety and
efficacy, compared with earlier devices (10–12). Therefore the
confirmation of the ability of the SXscore to independently
predict adverse clinical outcomes in any patient presenting for
PCI treated with second-generation DES is important evi-
dence to support the routine use of the SXscore in everyday
practice. This ability to identify those patients at greatest risk of
adverse events facilitates appropriate informed consent and
counseling while also prompting increased surveillance and
aggressive secondary preventive therapy and lifestyle modifica-
tions in those at highest risk.
Analysis of the SXscore distribution in the current study
clearly indicates that patients with very complex CAD are
being treated with PCI—a consequence of the increasing
age and comorbidities of patients presenting for revascular-
ization (21) and the advancements in PCI technology.
Objective evidence of this increase is reflected in the mean
SXscores of the SIRTAX (Sirolimus-Eluting Stent Com-
pared with Paclitaxel-Eluting Stent for Coronary Revascu-
larization) and LEADERS studies, which were 11.7  7.3
and 13.5  8.7 (3,6), respectively, compared with 14.6 
Table 3. Clinical Outcomes at 12 Months on an Intention-To-Treat Basis
Variable
SXscore <9
(n  698)
Death 1.9% (13)
Cardiac death 1.0% (7)
Any MI* 8.0% (56)
Any MI† 3.2% (22)
Target vessel MI† 2.7% (19)
Any repeat revascularization 5.0% (35)
Clinically indicated TLR 2.0% (14)
Death or MI 4.7% (33)
Target lesion failure‡ 5.2% (36)
Patient-oriented composite endpoint§ 8.5% (59)
ARC deﬁnite stent thrombosis 0.4% (3)
ARC deﬁnite/probable stent thrombosis 0.9% (6)
ARC any stent thrombosis 1.4% (10)
Values are given as % (n). *Defined according to the Academic Research Consortium (ARC) (18). †
nontarget vessel) and clinically indicated target lesion revascularization (TLR). §Patient-oriented co
Abbreviations as in Table 1.9.2 in the current study. Moreover, the percentage ofpatients with SXscores32, a group with the most complex
CAD and previously identified in the SYNTAX trial as the
threshold above which surgical revascularization provided
the optimal outcome, is also increasing with respective rates
of 1.0% and 2.9% in the SIRTAX and LEADERS studies,
compared with 4.4% in the present analysis. The current
study lacked a surgical control arm, and it is therefore not
possible to state whether PCI was appropriate for those
patients in the highest SXscore tertile. Moreover, at present,
no data are available comparing outcomes in patients
randomized to treatment with PCI with second-generation
DES or coronary artery bypass grafting; however, the utility
of using EES compared with coronary artery bypass grafting
in patients with complex CAD is currently being assessed in
the ongoing EXCEL (Evaluation of Xience Prime versus
Coronary Artery Bypass Surgery for Effectiveness of Left
Main Revascularization) study.
It is reassuring that no significant differences in mortality
were noted across SXscore tertiles, despite the more com-
plex patient population in the current study—a finding at
variance with the LEADERS study, which did identify the
SXscore as an independent predictor of mortality (3).
Furthermore, although both studies indicated significantly
higher rates of their respective primary study endpoints and
repeat revascularization in patients in the highest SXscore
tertile, the same was not true for MI in the LEADERS
study or ST in the current study. This variation in the ability
of the SXscore to predict “hard” clinical endpoints is not
clearly explained. Without doubt, it could be the conse-
quence of underpowered sub-group analyses (22,23); how-
ever, it might also reflect the limitations of using a risk
model assessing only 1 type of variable. Consistent with
9 <SXscore <17
(n  676)
SXscore >17
(n  659) p Value
1.0% (7) 2.7% (18) 0.25
0.4% (3) 2.1% (14) 0.06
12.1% (82) 18.2% (120) 0.0001
3.8% (26) 5.3% (39) 0.01
3.6% (24) 5.6% (37) 0.006
7.7% (52) 13.7% (90) 0.0001
2.7% (18) 5.3% (35) 0.0007
4.7% (32) 8.2% (54) 0.01
5.9% (40) 11.7% (77) 0.0001
11.2% (76) 20.0% (132) 0.0001
0.6% (4) 1.1% (7) 0.16
0.7% (5) 1.7% (11) 0.15
0.9% (6) 2.6% (17) 0.10
d historical definition (19). ‡Target lesion failure: cardiac death, MI† (not clearly attributable to a
endpoint: a composite of all-cause mortality, MI (Q- and non–Q-wave), or any revascularization.Extende
mpositeprevious studies (15,16), there were variations in the dis-
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438Figure 1. Kaplan-Meier Curves
Kaplan-Meier survival curves for (A) the patient-oriented composite endpoint (a composite of all-cause death, any myocardial infarction, and any repeat revascu-
larization; (B) any death; (C) any myocardial infarction; (D) any repeat revascularization out to 12-month follow-up. SXscore  SYNTAX score.
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439Figure 1. Continued.
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440criminatory ability of the SXscore, ACEF score, and CSS,
which represent an anatomical, clinical, and combination
clinical/anatomical risk model, respectively, depending on
the outcome measure being assessed. The C-statistic for
mortality was highest for the ACEF score, reflecting the
heavy influence of pre-morbid characteristics on this out-
come. Similarly, the C-statistic for repeat revascularization
was highest for the SXscore. One of the previous valid
concerns with using the SXscore is the absence of clinical
variables in its calculation, a deficiency that can be corrected
through its combination with a clinically based score as
reported previously (16,24) and highlighted in the present
study through the improved C-statistics for all outcomes,
apart from repeat revascularization, when using the CSS
compared with the SXscore.
The rates of definite ST in the current study were lower
than those seen in corresponding tertiles of the SXscore in
the LEADERS study, differences that might partly explain
the lack of association between ST and SXscore tertile in the
present study. It must be acknowledged that the current
study is underpowered to assess for this outcome; however,
the numerically different rates of ST according to SXscore
tertiles—despite comparable duration of DAPT—suggest
that there might be an additional role for the SXscore in
helping tailor antiplatelet therapy on an individual level.
However, confirmation of this hypothesis requires ade-
quately powered randomized trials.
The 12-month outcomes from the RESOLUTE All
Comers study demonstrated that R-ZES was noninferior to
EES with respect to the primary clinical endpoint of TLF.
The present study reassuringly indicates that comparable
outcomes with respect to TLF were also maintained be-
tween both stents irrespective of the severity of underlying
CAD. Of note, although the between-stent differences in
mortality and definite ST amongst patients in the highest
SXscore tertile followed the trends seen in the full patient
cohort, the same was not true for the differences seen in
clinically indicated TLR. Similarly, in the LEADERS study, a
Table 4. Cox Multivariate Analysis
Clinical Outcome
Hazard Ratio for SYNTAX Score*
(95% Confidence Interval) p Value
Death 1.19 (0.80–1.76) 0.40
MI† 1.52 (1.17–1.99) 0.002
Any repeat revascularization 1.75 (1.44–2.13) 0.001
Target lesion failure‡ 1.68 (1.36–2.06) 0.001
Patient-oriented composite
endpoint§
1.68 (1.43–1.96) 0.001
Any stent thrombosis 1.39 (0.89–2.15) 0.15
*After adjustment of confounding factors: age65 years, sex, presentation with an acute myo-
cardial infarction (MI), presence of diabetes, and stent type. †Extended historical definition (19).
‡Target lesion failure: cardiac death, MI† (not clearly attributable to a nontarget vessel) and
clinically indicated target lesion revascularization (TLR).§Patient-oriented composite endpoint: acomposite of all-cause mortality, MI (Q- and non–Q-wave), or any revascularization.significant between-stent difference in cardiac death was
observed amongst patients in the highest SXscore tertile,
which was not seen in the full patient cohort (25). Although
these observations might suggest potential differences in
stent performance with different severities of CAD, they
should be regarded in the first instance as being underpow-
ered, hypothesis-generating analyses and should ultimately
be used as a stimulus for further more-directed and ade-
quately powered studies. Nevertheless, these observations
do serve to highlight a new potential application of the
SXscore as a means to further assess and compare the
performance of new coronary devices.
Study limitations. The SXscore has several limitations, in-
luding intraobserver and interobserver variability (2,26)—
hich is inherent to its subjective derivation with coronary
ngiography—and the absence of specific algorithms for
atients with prior percutaneous or surgical revasculariza-
ion. Specifically, the current analysis might have limita-
ions, such as underpowered results and chance findings,
hich are inherent to the use of sub-group analysis (22,23).
issing quantitative values for the ejection fraction and
erum creatinine also lead to the ACEF score and CSS
eing available in only approximately one-half of the study
opulation.
onclusions
The SXscore is able to stratify risk amongst an all-comers
population treated with PCI with second-generation DES;
however, improvements can be made with the inclusion of
Table 5. Comparison of Discriminatory Ability of SXscore, ACEF Score,
and Clinical SYNTAX Score
C-Statistic
Variable
SXscore
(n  2,033)
ACEF Score
(n  1,218)
CSS
(n  1,098)
Death 0.57 0.78 0.67
Cardiac death 0.61 0.84 0.71
Any myocardial infarction* 0.60 0.58 0.65
Any repeat
revascularization
0.63 0.50 0.59
Target lesion failure† 0.62 0.59 0.63
Patient-oriented
composite endpoint‡
0.62 0.56 0.63
ARC any stent thrombosis 0.60 0.72 0.68
*Extended historical definition (19). †Target lesion failure: cardiac death, myocardial infarction
(MI)* (not clearly attributable to a nontarget vessel), and clinically indicated target lesion revas-
cularization (TLR). ‡Patient-oriented composite endpoint: a composite of all-cause mortality, MI
(Q- and non–Q-wave), or any revascularization.
ACEF score  Age, Creatinine and Ejection Fraction; CSS  clinical SYNTAX score; SXscore 
SYNTAX score.clinical variables.
11
1
1
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 4 , 2 0 1 1 Garg et al.
A P R I L 2 0 1 1 : 4 3 2 – 4 1 SYNTAX Score in the RESOLUTE All Comers Trial
441Reprint requests and correspondence: Dr. Patrick W. Serruys,
Department of Interventional Cardiology, Erasmus Medical
Center, Ba583a, Thoraxcenter, Erasmus Medical Center,
’s-Gravendijkwal 230, 3015 CE, Rotterdam, Zuid Holland, the
Netherlands. E-mail: p.w.j.c.serruys@erasmusmc.nl.
REFERENCES
1. Sianos G, Morel MA, Kappetein AP, et al. The SYNTAX Score: an
angiographic tool grading the complexity of coronary artery disease.
EuroIntervention 2005;1:219–27.
2. Serruys PW, Onuma Y, Garg S, et al. Assessment of the SYNTAX
score in the Syntax study. EuroIntervention 2009;5:50–6.
3. Wykrzykowska J, Garg S, Girasis C, et al. Value of the SYNTAX score
for risk assessment in the all-comers population of the randomized
multicenter LEADERS (Limus Eluted from A Durable versus
ERodable Stent coating) trial. J Am Coll Cardiol 2010;56:272–7.
4. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
intervention versus coronary artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961–72.
5. Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C,
Tamburino C. Usefulness of the SYNTAX score for predicting clinical
outcome after percutaneous coronary intervention of unprotected left
main coronary artery disease. Circ Cardiovasc Interv 2009;2:302–8.
6. Girasis C, Garg S, Raber L, et al. Prediction of 5-year clinical
outcomes using the SYNTAX score in patients undergoing PCI from
the sirolimus eluting stent compared with paclitaxel eluting stent for
coronary revascularisation (SIRTAX) trial. Presented at: American
College of Cardiology meeting; March 14–16, 2010; Atlanta, GA.
7. Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the
ARTS Series II (Arterial Revascularization Therapies Study II) of the
sirolimus-eluting stent in the treatment of patients with multivessel de
novo coronary artery lesions. J Am Coll Cardiol 2010;55:1093–101.
8. Onuma Y, Girasis C, Piazza N, et al. Long-term clinical results
following stenting of the left main stem: insights from RESEARCH
(Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hos-
pital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardi-
ology Hospital) registries. J Am Coll Cardiol Intv 2010;3:584–94.
9. Garg S, Sarno G, Serruys PW, et al. Prediction of 1-year clinical
outcomes using the SYNTAX score in patients with acute ST-
elevation myocardial infarction undergoing primary PCI: a sub-study of
the STRATEGY and MULTI-STRATEGY trials. J Am Coll Cardiol
Intv 2011;4:66–75.
10. Garg S, Serruys PW. Coronary stents—current status. J Am Coll
Cardiol 2010;56:S1–S42.
11. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus
paclitaxel-eluting stents in coronary artery disease. N Engl J Med
2010;362:1663–74.12. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation
everolimus-eluting and paclitaxel-eluting stents in real-life practice
(COMPARE): a randomised trial. Lancet 2010;375:201–9.
13. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting
and everolimus-eluting coronary stents. N Engl J Med 2010;363:123–35.
4. Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G.
Risk of assessing mortality risk in elective cardiac operations: age,
creatinine, ejection fraction, and the law of parsimony. Circulation
2009;119:3053–61.
5. Wykrzykowska J, Garg S, Onuma Y, et al. Value of Age, Creatinine
and Ejection Fraction (ACEF score) in assessing risk in patients
undergoing percutaneous coronary interventions in an “all-comers”
LEADERS trial. Circ Cardiovasc Interv 2011;4:47–56.
6. Garg S, Sarno G, Garcia-Garcia HM, et al. A new tool for the risk
stratification of patients with complex coronary artery disease: the
clinical SYNTAX score. Circ Cardiovasc Interv 2010;3:317–26.
7. SYNTAX working-group. SYNTAX score calculator. Available at:
http://www.syntaxscore.com. Accessed July 21, 2010.
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in
coronary stent trials: a case for standardized definitions. Circulation
2007;115:2344–51.
19. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction
adjudication in contemporary all-comer stent trials: balancing sensitiv-
ity and specificity. EuroIntervention 2010;5:871–4.
20. Kim Y-H, Park D-W, Kim W-J, et al. Validation of SYNTAX
(Synergy between PCI with Taxus and Cardiac Surgery) score for
prediction of outcomes after unprotected left main coronary revascu-
larization. J Am Coll Cardiol Intv 2010;3:612–23.
21. Hilliard AA, From AM, Lennon RJ, et al. Percutaneous revascular-
ization for stable coronary artery disease temporal trends and impact of
drug-eluting stents. J Am Coll Cardiol Intv 2010;3:172–9.
22. Lagakos SW. The challenge of subgroup analyses—reporting without
distorting. N Engl J Med 2006;354:1667–9.
23. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in
medicine—reporting of subgroup analyses in clinical trials. N Engl
J Med 2007;357:2189–94.
24. Capodanno D, Miano M, Cincotta G, et al. EuroSCORE refines the
predictive ability of SYNTAX score in patients undergoing left main
percutaneous coronary intervention. Am Heart J 2010;159:103–9.
25. Wykrzykowska J, Garg S, Onuma Y, et al. Implantation of the
biodegradable polymer biolimus eluting stent in patients with high
SYNTAX score is associated with decreased cardiac mortality com-
pared to permanent polymer sirolimus eluting stent. Two year
follow-up results from the all-comers LEADERS trial. EuroInterven-
tion 2011. In press.
26. Garg S, Girasis C, Sarno G, et al. The SYNTAX score revisited: A
reassessment of the SYNTAX score reproducibility. Catheter Cardio-
vasc Interv 2010;75:946–52.
Key Words: everolimus-eluting stent(s)  resolute
zotarolimus-eluting stent(s)  SYNTAX score.
